LLY vs NVDA: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and NVIDIA Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
NVIDIA Corporation · Technology
$225.07
+45.0% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
NVDA |
| Current Price |
$1,183.72 |
$225.07 |
| Fair Value Estimate |
$1,208.00 |
$326.35 |
| Upside to Fair Value |
+2.1%
|
+45.0%
|
| Market Cap |
$1,114.8B |
$5,451.4B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
23.4x
|
| Price / Sales |
14.0x
|
18.0x
|
| Price / FCF |
52.7x
|
42.9x
|
| Revenue Growth YoY |
+47.7%
|
+105.9%
|
| Gross Margin |
83.4%
|
74.7%
|
| Operating Margin |
49.7%
|
65.2%
|
| Return on Equity |
92.6%
|
110.1%
|
| Dividend Yield |
0.57% |
0.23% |
| FCF Yield |
1.9%
|
2.33%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
NVIDIA designs the accelerated computing platforms at the center of the AI buildout, spanning data center GPUs, Mellanox networking, AI enterprise software, gaming GeForce GPUs, professional visualization, and automotive platforms, with 42,000 employees and a $5.45 trillion market capitalization. Business quality is exceptional on the fundamentals: TTM gross margin of 74.7%, TTM operating margin …
Accumulation Zones
| Metric |
LLY |
NVDA |
| Zone Low |
$906.00 |
$244.76 |
| Zone High |
$1,026.80 |
$277.40 |
| In Buy Zone? |
No
|
Yes
|